Otsuka Pharmaceutical To Acquire Transcend Therapeutics, Pay $700 Million To Shareholders Upon Acquisition
27/03/2026 09:05
March 27 (Reuters) - Otsuka Holdings Co Ltd 4578.T: OTSUKA HOLDINGS CO LTD: OTSUKA PHARMACEUTICAL TO ACQUIRE TRANSCEND THERAPEUTICS OTSUKA HOLDINGS CO - OTSUKA PHARMACEUTICAL WILL PAY USD 700 MILLION TO THE SHAREHOLDERS OF TRANSCEND UPON COMPLETION OF THE ACQUISITION, AS WELL AS UP TO AN ADDITIONAL USD 525 MILLION IN NET SALES MILESTONES Source text: ID:nTSoa90822 Further company coverage: 4578.T
Recent news on Otsuka Holdings
See all newsOtsuka, Ionis' experimental ALS drug meets main goal in late-stage study
Brief: Otsuka Pharmaceutical Announces Ulefnersen Early Access Program For Eligible People Living With FUS-ALS
Brief: Otsuka Pharmaceutical Says Phase 3 Fusion Results For Ulefnersen Met Primary Endpoint
Zipalertinib Plus Chemotherapy Demonstrates 6-Month Median Progression-Free Survival Benefit In Rezilient3 Phase 3 Trial In First-Line Egfr Exon 20 Insertion Mutation Non-Small Cell Lung Cancer
Climb Bio rises after early-stage data for kidney disease drug